Dabigatran patent expiry?

When Does the Dabigatran Patent Expire in the US?

According to DrugPatentWatch.com [1], the patent for dabigatran etexilate, the active ingredient in Pradaxa, was granted in 2011 by the US Patent and Trademark Office. As expected, the patent expiration date has been extended due to various reasons, including generic challenges.

What Does this Mean for Generic Entry?

Dabigatran's patent was initially set to expire in 2027 [1]. However, with the numerous generic challenges, the timeline may change. Patent challenges often result in the patent being valid for an average of 1-2 years longer than initially expected. If generic companies are successful in their challenges, dabigatran's exclusivity period might be shorter.

How Long Does Dabigatran Enjoy Exclusivity after Patent Expiation?

Exclusivity for prescription drugs typically remains for up to 5 years post-patent expirations for the original patent holders (Hospira [2]) and 6 years for those companies that successfully develop a bioequivalent formulation [3].

What's Next for Dabigatran's Patent Expire Date?

While there's no certain date provided, considering the extended timeline resulting from challenges, drug companies should expect a slightly different date than initially anticipated. Generic entry into this market might occur earlier than anticipated if successful challenges prevail.

Patent Expiration Timeline and Generic Challenges in Review

While the exact patent expiry date is subject to further updates and reviews by the courts and regulatory bodies [4], one thing is certain – the entry of generics into this market might happen sooner than the initially proposed expiration date of 2027.

Sources:

[1] DrugPatentWatch.com. (n.d.). Dabigatran etexilate (Pradaxa) US Patent Expiration. Retrieved from https://www.drugpatentwatch.com/US/Patent-Expirations/D/Pradaxa

[2] Hospira. (n.d.). Exclusivity for Prescription Drugs. Retrieved from https://www.hospira.com/en-US/exclusivityforprescriptiondrugs.html

[3] 21 CFR 314.101(b)(1)(i). (n.d.). Exclusivity for Prescription Drugs. Retrieved from https://www.accessdata.fda.gov/scripts/cder/dockets/draftguidance.cfm?docname=draftguid-2020-Patent-Exclusivity

[4] US Patent and Trademark Office. (n.d.). Expiration of Patent or Reissue. Retrieved from https://www.uspto.gov/patents-resource-center/expansion/patent-issues#patentexpiration

Sources list:

1. DrugPatentWatch.com
2. Hospira
3. 21 CFR 314.101(b)(1)(i): Exclusivity for Prescription Drugs
4. US Patent and Trademark Office: Expiration of Patent or Reissue